2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. (December 2022) - Gettinger, S.; Schenker, M.; De Langen, J.; Fischer, J.R.; Morgensztern, D.; Ciuleanu, T-E.; Beck, T.; De Castro Carpeno, J.; Schumann, C.; Yang, X.; Telivala, B.; Deschepper, K.; et al.